[1] |
ZHAO H, ALAM A, SOO AP, et al. Ischemia-reperfusion injury reduces long term renal graft survival: mechanism and beyond[J]. EBioMedicine, 2018, 28: 31-42. DOI: 10.1016/j.ebiom.2018.01.025.
|
[2] |
袁强, 申开文, 张瑞波, 等. NLRP3炎症小体与相关炎症信号通路在肾缺血-再灌注损伤中的作用[J]. 器官移植, 2021, 12(2): 177-183. DOI: 10.3969/j.issn.1674-7445.2021.02.007.YUAN Q, SHEN KW, ZHANG RB, et al. Role of NLRP3 inflammasome and related inflammatory signaling pathways in renal ischemia-reperfusion injury[J]. Organ Transplant, 2021, 12(2): 177-183. DOI: 10.3969/j.issn.1674-7445.2021.02.007.
|
[3] |
BORTOLOTTI P, FAURE E, KIPNIS E. Inflammasomes in tissue damages and immune disorders after trauma[J]. Front Immunol, 2018, 9: 1900. DOI: 10.3389/fimmu.2018.01900.
|
[4] |
WANG Z, ZHANG S, XIAO Y, et al. NLRP3 inflammasome and inflammatory diseases[J]. Oxid Med Cell Longev, 2020: 4063562. DOI: 10.1155/2020/4063562.
|
[5] |
EFFERTH T, DUNSTAN H, SAUERBREY A, et al. The anti-malarial artesunate is also active against cancer[J]. Int J Oncol, 2001, 18(4): 767-773. DOI: 10.3892/ijo.18.4.767.
|
[6] |
KAPTEIN SJ, EFFERTH T, LEIS M, et al. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo[J]. Antiviral Res, 2006, 69(2): 60-69. DOI: 10.1016/j.antiviral.2005.10.003.
|
[7] |
VERMA S, KUMAR VL. Artesunate affords protection against aspirin-induced gastric injury by targeting oxidative stress and proinflammatory signaling[J]. Pharmacol Rep, 2018, 70(2): 390-397. DOI: 10.1016/j.pharep.2017.06.003.
|
[8] |
FENG FB, QIU HY. Effects of artesunate on chondrocyte proliferation, apoptosis and autophagy through the PI3K/Akt/mTOR signaling pathway in rat models with rheumatoid arthritis[J]. Biomed Pharmacother, 2018, 102: 1209-1220. DOI: 10.1016/j.biopha.2018.03.142.
|
[9] |
LIU Z, QU M, YU L, et al. Artesunate inhibits renal ischemia-reperfusion-mediated remote lung inflammation through attenuating ROS-induced activation of NLRP3 inflammasome[J]. Inflammation, 2018, 41(4): 1546-1556. DOI: 10.1007/s10753-018-0801-z.
|
[10] |
PELLEGRINI C, FORNAI M, COLUCCI R, et al. A comparative study on the efficacy of NLRP3 inflammasome signaling inhibitors in a pre-clinical model of bowel inflammation[J]. Front Pharmacol, 2018, 9: 1405. DOI: 10.3389/fphar.2018.01405.
|
[11] |
闫林轩, 梅霄阳, 章林明, 等. G蛋白偶联雌激素受体通过减轻大鼠肾小管上皮细胞凋亡保护肾脏缺血再灌注损伤[J]. 实用医学杂志, 2021, 37(10): 1235-1239. DOI: 10.3969/j.issn.1006-5725.2021.10.001.YAN LX, MEI XY, ZHANG LM, et al. GPER protects renal ischemia-reperfusion injury by reducing the apoptosis of renal tubular epithelial cells in rats[J]. J Pract Med, 2021, 37(10): 1235-1239. DOI: 10.3969/j.issn.1006-5725.2021.10.001.
|
[12] |
RABB H, GRIFFIN MD, MCKAY DB, et al. Inflammation in AKI: current understanding, key questions, and knowledge gaps[J]. J Am Soc Nephrol, 2016, 27(2): 371-379. DOI: 10.1681/ASN.2015030261.
|
[13] |
CHEN H, FANG Y, WU J, et al. RIPK3-MLKL-mediated necroinflammation contributes to AKI progression to CKD[J]. Cell Death Dis, 2018, 9(9): 878. DOI: 10.1038/s41419-018-0936-8.
|
[14] |
DING J, WANG K, LIU W, et al. Pore-forming activity and structural autoinhibition of the gasdermin family[J]. Nature, 2016, 535(7610): 111-116. DOI: 10.1038/nature18590.
|
[15] |
田梦蕾, 马梦茜, 刘茂东. 细胞焦亡与肾脏疾病[J]. 中华生物医学工程杂志, 2021, 27(1): 94-97. DOI: 10.3760/cma.j.cn115668-20190604-00071.TIAN ML, MA MQ, LIU MD. The role of pyroptosis in renal diseases[J]. Chin J Biomed Eng, 2021, 27(1): 94-97. DOI: 10.3760/cma.j.cn115668-20190604-00071.
|
[16] |
LU F, LAN Z, XIN Z, et al. Emerging insights into molecular mechanisms underlying pyroptosis and functions of inflammasomes in diseases[J]. J Cell Physiol, 2020, 235(4): 3207-3221. DOI: 10.1002/jcp.29268.
|
[17] |
SHI J, ZHAO Y, WANG K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death[J]. Nature, 2015, 526(7575): 660-665. DOI: 10.1038/nature15514.
|
[18] |
ROGERS C, ALNEMRI ES. Gasdermins: novel mitochondrial pore-forming proteins[J]. Mol Cell Oncol, 2019, 6(5): e1621501. DOI: 10.1080/23723556.2019.1621501.
|
[19] |
ANDERS HJ. Of inflammasomes and alarmins: IL-1β and IL-1α in kidney disease[J]. J Am Soc Nephrol, 2016, 27(9): 2564-2575. DOI: 10.1681/ASN.2016020177.
|
[20] |
ANDRADE-OLIVEIRA V, FORESTO-NETO O, WATANABE IKM, et al. Inflammation in renal diseases: new and old players[J]. Front Pharmacol, 2019, 10: 1192. DOI: 10.3389/fphar.2019.01192.
|
[21] |
WEN Y, LIU YR, TANG TT, et al. mROS-TXNIP axis activates NLRP3 inflammasome to mediate renal injury during ischemic AKI[J]. Int J Biochem Cell Biol, 2018, 98: 43-53. DOI: 10.1016/j.biocel.2018.02.015.
|
[22] |
LIU JJ, LU L, HU FQ, et al. Methylene blue attenuates renal ischemia-reperfusion injury by negative regulation of NLRP3 signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2018, 22(9): 2847-2853. DOI: 10.26355/eurrev_201805_14986.
|
[23] |
HUTTON HL, OOI JD, HOLDSWORTH SR, et al. The NLRP3 inflammasome in kidney disease and autoimmunity[J]. Nephrology (Carlton), 2016, 21(9): 736-744. DOI: 10.1111/nep.12785.
|
[24] |
FAN S, ZHANG D, LIU F, et al. Artesunate alleviates myocardial ischemia/reperfusion-induced myocardial necrosis in rats and hypoxia/reoxygenation-induced apoptosis in H9C2 cells via regulating the FAK/PI3K/Akt pathway[J]. Ann Transl Med, 2020, 8(20): 1291. DOI: 10.21037/atm-20-5182.
|
[25] |
CHEN Y, WU J, ZHU J, et al. Artesunate provides neuroprotection against cerebral ischemia-reperfusion injury via the TLR-4/NF-κB pathway in rats[J]. Biol Pharm Bull, 2021, 44(3): 350-356. DOI: 10.1248/bpb.b20-00604.
|
[26] |
ZHANG K, YANG Y, GE H, et al. Artesunate promotes the proliferation of neural stem/progenitor cells and alleviates ischemia-reperfusion injury through PI3K/Akt/Foxo-3a/p27kip1 signaling pathway[J]. Aging (Albany NY), 2020, 12(9): 8029-8048. DOI: 10.18632/aging.103121.
|
[27] |
SUN Z, MA Y, CHEN F, et al. Artesunate ameliorates high glucose-induced rat glomerular mesangial cell injury by suppressing the TLR4/NF-κB/NLRP3 inflammasome pathway[J]. Chem Biol Interact, 2018, 293: 11-19. DOI: 10.1016/j.cbi.2018.07.011.
|